Goserelin
Hormonal / ClinicalAlso known as: Zoladex
Mechanism
A GnRH agonist delivered as a tiny implant injected under the skin of the abdomen. It initially stimulates and then shuts down the body's sex hormone production — effectively a chemical castration used to treat prostate cancer, breast cancer, and endometriosis. Available as 1-month or 3-month implants.
Technical detail
Synthetic GnRH decapeptide agonist with D-Ser(tBu)6 and AzGly10 substitutions conferring protease resistance. Potent GnRHR agonist — initial flare phase (1-2 weeks) increases LH/FSH release, followed by GnRHR downregulation and desensitization via receptor internalization and uncoupling from Gq/G11 signaling. Continuous exposure reduces GnRH pulse frequency requirement, causing pituitary GnRHR loss and profound hypogonadism (testosterone <20 ng/dL in men, estradiol to postmenopausal levels in women). Delivered as biodegradable PLGA implant (3.6 mg monthly or 10.8 mg every 3 months) providing zero-order release kinetics. Implant is pre-loaded in a 16-gauge needle for SC abdominal wall injection.
Effects
**Endocrine — HPG Axis (Tier 1 — Human Clinical):** Goserelin is a GnRH agonist that initially stimulates LH/FSH release (causing a testosterone/estrogen flare lasting 1–2 weeks), followed by GnRH receptor downregulation and profound gonadal suppression. Testosterone reaches castrate levels (<50 ng/dL) within 2–4 weeks. Estradiol suppression to postmenopausal levels occurs in women within 3–4 weeks. **Reproductive / Prostate (Tier 1 — Human Clinical):** Standard androgen deprivation therapy for advanced prostate cancer. Equivalent efficacy to surgical orchiectomy for testosterone suppression. Also used in breast cancer (premenopausal hormone receptor-positive) for ovarian suppression. **Reproductive — Female (Tier 1 — Human Clinical):** Creates medical menopause when used in women. Used for endometriosis (reduces estrogen-dependent endometrial implant growth), uterine fibroids (shrinks fibroids pre-operatively), and as part of IVF protocols (pituitary downregulation before controlled ovarian stimulation). **Musculoskeletal (Tier 1 — Side Effect):** Bone mineral density loss of 2–6% per year during treatment due to hypogonadism. Affects both men and women. Reversible in women after discontinuation; less reversible in men on long-term ADT. **Metabolic (Tier 1 — Side Effect):** Weight gain, insulin resistance, lipid profile worsening, and increased cardiovascular risk during chronic goserelin therapy. Part of the metabolic syndrome of androgen deprivation. **Vasomotor (Tier 1 — Side Effect):** Hot flashes in >70% of patients (both men and women) due to gonadal hormone suppression. Can be severe and treatment-limiting.
Practitioner Guide
**APPROVED INDICATIONS:** • Advanced prostate cancer (androgen deprivation therapy). • Breast cancer (premenopausal, hormone receptor-positive) — ovarian suppression. • Endometriosis — symptom management and disease regression. • Endometrial thinning prior to ablation. **DOSING:** • 3.6 mg subcutaneous implant every 28 days (standard). • 10.8 mg subcutaneous implant every 12 weeks (extended release, prostate cancer). • Administered via pre-loaded syringe into anterior abdominal wall subcutaneous tissue. The implant is a biodegradable depot. **FLARE MANAGEMENT (Deep Clinical Guidance):** • The testosterone flare with GnRH agonists like goserelin lasts 7–14 days and can cause: bone pain exacerbation, urinary obstruction, spinal cord compression (in metastatic prostate cancer), and disease flare in breast cancer. • Standard flare prevention: Start anti-androgen (bicalutamide 50 mg daily for men, or tamoxifen for women) 1–2 weeks BEFORE first goserelin injection. Continue for 2–4 weeks after. • In high-risk patients (symptomatic metastases, impending cord compression): Consider degarelix instead — no flare with GnRH antagonists. If goserelin must be used, ensure anti-androgen cover is initiated and admission for monitoring may be warranted. • Clinical pearl: After the first injection, subsequent goserelin doses do NOT cause significant flare because pituitary GnRH receptors are already downregulated. Flare is only clinically relevant with the initial dose. **BONE DENSITY MONITORING DURING LONG-TERM USE:** • Baseline DEXA scan before starting or within first 3 months. • Repeat DEXA every 1–2 years during treatment (same as degarelix recommendations). • Bone protective measures: Calcium 1200 mg/day + vitamin D 1000–2000 IU/day. Consider bisphosphonate (zoledronic acid 4 mg IV annually) or denosumab (Prolia 60 mg SC every 6 months) for osteopenia or osteoporosis. • Weight-bearing and resistance exercise essential. • In women using goserelin for endometriosis: Treatment limited to 6 months without add-back therapy due to bone loss concerns (see add-back therapy below). **ADD-BACK THERAPY FOR WOMEN:** • For endometriosis treatment beyond 6 months, "add-back" therapy is standard: low-dose norethindrone acetate 5 mg daily (most common) or low-dose conjugated estrogens 0.625 mg + norethindrone 5 mg daily. • Add-back protects bone density and reduces vasomotor symptoms (hot flashes) while maintaining therapeutic suppression of endometriosis — the "floor" of estrogen needed for endometriosis regression is lower than the level needed for bone protection. • Clinical pearl: Add-back therapy does NOT reduce goserelin efficacy for endometriosis. The "estrogen threshold hypothesis" shows that endometriosis requires higher estrogen levels than bone maintenance. Start add-back from Day 1 of goserelin treatment — there is no benefit to delayed add-back. • For IVF: No add-back needed as goserelin is used only for 2–3 weeks of pituitary downregulation. **THE TRIPTORELIN PCT PHENOMENON (Off-Label Context):** • In the bodybuilding/anabolic steroid community, a single small dose (100 mcg) of triptorelin (another GnRH agonist) has been proposed as a "PCT reset" — the theory being that a single dose causes a massive LH/FSH surge that restarts endogenous testosterone production suppressed by steroid use. • This practice is DANGEROUS and pharmacologically flawed: (1) The LH surge is followed by receptor downregulation and suppression if the dose is too high. (2) A single 100 mcg dose of triptorelin is still far above what's needed for the initial stimulatory phase and can cause prolonged suppression. (3) There are case reports of prolonged hypogonadism after single-dose triptorelin "PCT." • Goserelin is NOT used for PCT and should NOT be — its depot formulation causes sustained castrate-level suppression for weeks. • Proper PCT uses SERMs (clomiphene, tamoxifen) and/or hCG, not GnRH agonists. The triptorelin PCT concept has no clinical evidence supporting it and significant risk of harm.
Research Summary
**Tier 1 (Human Clinical Evidence):** • Prostate cancer: Decades of data. Non-inferior to orchiectomy for testosterone suppression. Multiple Phase III trials and meta-analyses confirm long-term survival outcomes equivalent to other ADT methods. • Endometriosis: RCTs demonstrate significant pain reduction and disease regression. Limited to 6 months without add-back therapy. • Breast cancer: SOFT and TEXT trials confirm ovarian suppression (with goserelin or equivalent) + endocrine therapy improves outcomes in premenopausal HR+ breast cancer. • IVF: Standard component of long-protocol IVF stimulation regimens. Well-established efficacy for pituitary downregulation. **Tier 2 (Strong Preclinical + Mechanistic):** • GnRH receptor downregulation mechanism is textbook endocrinology — well-characterized at molecular level. • Cardiovascular risk of ADT: Epidemiological data shows increased MI, stroke, and sudden cardiac death with GnRH agonists. Mechanism involves metabolic syndrome induction and possibly direct FSH effects on vasculature. **Tier 3 (Emerging / Theoretical):** • Whether GnRH agonists carry higher cardiovascular risk than GnRH antagonists is actively debated. PRONOUNCE trial showed no significant difference, but was underpowered.